BPIQ API + MCP Documentation

Sample Response

{
  "count": 532,
  "next": "https://api.bpiq.com/api/v1/info/drugs/?limit=30&offset=30",
  "previous": null,
  "results": [
    {
      "id": 272,
      "company": {
        "ticker": "AMRX",
        "name": "Amneal Pharmaceuticals Inc.",
        "last_price": "14.49",
        "market_cap": 4558262272
      },
      "ticker": "AMRX",
      "drug_name": "Denosumab Biosimilars",
      "indications": [
        {
          "id": 808,
          "title": "Osteoporosis",
          "nickname": ""
        }
      ],
      "indications_text": "Osteoporosis",
      "stage_event": {
        "id": 47,
        "label": "Approved Quarterly sales",
        "stage_label": "Approved",
        "event_label": "Quarterly sales"
      },
      "note": "Denosumab biosimilar candidates reference Prolia(R) and XGEVA(R). 3/4/25- BLA accepted. PDUFA target action date Q4 2025. 8/7/25- Ongoing development. 12/22/25:- FDA approved Boncresa and Oziltus denosumab biosimilars. Prolia/XGEVA U.S. sales ~$5.3B annually.",
      "catalyst_date": null,
      "has_catalyst": true,
      "catalyst_source": "https://www.globenewswire.com/news-release/2025/12/22/3209543/0/en/Amneal-Announces-FDA-Approval-of-Denosumab-Biosimilars-Referencing-Prolia-and-XGEVA.html",
      "is_big_mover": false,
      "is_suspected_mover": false,
      "is_hedge_fund_pick": false,
      "is_hedge_fund_avoid": false,
      "is_high_mgmt_interest": false
    }
  ]
}

Sample Response

{
  "count": 532,
  "next": "https://api.bpiq.com/api/v1/info/catalysts/?limit=30&offset=30",
  "previous": null,
  "results": [
    {
      "id": 272,
      "company": {
        "ticker": "AMRX",
        "name": "Amneal Pharmaceuticals Inc.",
        "last_price": "14.49",
        "market_cap": 4558262272
      },
      "ticker": "AMRX",
      "drug_name": "Denosumab Biosimilars",
      "indications": [
        {
          "id": 808,
          "title": "Osteoporosis",
          "nickname": ""
        }
      ],
      "indications_text": "Osteoporosis",
      "stage_event": {
        "id": 47,
        "label": "Approved Quarterly sales",
        "stage_label": "Approved",
        "event_label": "Quarterly sales"
      },
      "note": "Denosumab biosimilar candidates reference Prolia(R) and XGEVA(R). 3/4/25- BLA accepted. PDUFA target action date Q4 2025. 8/7/25- Ongoing development. 12/22/25:- FDA approved Boncresa and Oziltus denosumab biosimilars. Prolia/XGEVA U.S. sales ~$5.3B annually.",
      "catalyst_date": null,
      "has_catalyst": true,
      "catalyst_source": "https://www.globenewswire.com/news-release/2025/12/22/3209543/0/en/Amneal-Announces-FDA-Approval-of-Denosumab-Biosimilars-Referencing-Prolia-and-XGEVA.html",
      "is_big_mover": false,
      "is_suspected_mover": false,
      "is_hedge_fund_pick": false,
      "is_hedge_fund_avoid": false,
      "is_high_mgmt_interest": false
    }
  ]
}

Sample Response

{
  "count": 35,
  "data": [
    {
      "_id": "NCT07398417",
      "acronym": "FORWARD",
      "brief_summary": "The study is a Phase 3, double-blind, placebo-controlled, randomized withdrawal study to assess the efficacy and safety of AXS-14 in the management of fibromyalgia.",
      "conditions_list": [
        "Fibromyalgia"
      ],
      "first_posted_date": "2026-02-09 00:00:00",
      "in_airtable": true,
      "intereventions_list": [
        {
          "intervention_name": "AXS-14 (Esreboxetine)",
          "intervention_type": "DRUG"
        },
        {
          "intervention_name": "Placebo",
          "intervention_type": "DRUG"
        }
      ],
      "last_script_update": "2026-03-03 09:38:14.579000",
      "last_updated_date": "2026-02-09 00:00:00",
      "mapped_conditions_list": [
        {
          "condition_name": "Fibromyalgia",
          "disease_areas": [
            "Musculoskeletal Diseases",
            "Nervous System Diseases",
            "Inflammatory disorders"
          ]
        }
      ],
      "meta": {
        "count": {
          "total": 35
        }
      },
      "nctid": "NCT07398417",
      "phases_list": [
        "PHASE3"
      ],
      "primary_completion_date": "2028-03-01 00:00:00",
      "sponsors_list": [
        {
          "name": "Axsome Therapeutics, Inc.",
          "ticker": "AXSM",
          "class": "INDUSTRY",
          "ipo_status": "Public",
          "website": "https://www.axsome.com/"
        }
      ],
      "status": "RECRUITING",
      "study_url": "https://clinicaltrials.gov/study/NCT07398417",
      "tags": [],
      "title": "A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Assess the Efficacy and Safety of AXS-14 in the Management of Fibromyalgia"
    }
  ]
}

Sample Response

[
  {
    "id": 60855,
    "company": {
      "id": 337,
      "ticker": "AXSM",
      "name": "Axsome Therapeutics Inc."
    },
    "fund_name": "RTW INVESTMENTS, LP",
    "filing_date": "2026-02-17",
    "value": 162184000,
    "num_shares": 888001,
    "class_title": "COM",
    "name_of_issuer": "AXSOME THERAPEUTICS INC",
    "filing": 541
  },
  {
    "id": 63000,
    "company": {
      "id": 337,
      "ticker": "AXSM",
      "name": "Axsome Therapeutics Inc."
    },
    "fund_name": "PERCEPTIVE ADVISORS LLC",
    "filing_date": "2026-02-17",
    "value": 27195000,
    "num_shares": 148900,
    "class_title": "COM",
    "name_of_issuer": "AXSOME THERAPEUTICS INC",
    "filing": 555
  }
]

Sample Response

{
  "count": 6631,
  "next": "https://api.bpiq.com/api/v1/info/historical-catalysts/?limit=30&offset=0",
  "previous": null,
  "results": [
    {
      "id": 6406,
      "company": {
        "id": 454,
        "ticker": "PTGX",
        "name": "Protagonist Therapeutics "
      },
      "created_at": "2026-01-06T13:04:07.375336Z",
      "updated_at": "2026-02-27T13:04:46.865717Z",
      "ticker": "PTGX",
      "drug_name": "Rusfertide",
      "drug_indication": "Polycythemia Vera",
      "airtable_id": 6729,
      "stage": "NDA Filing",
      "catalyst_date": null,
      "catalyst_source": "https://www.businesswire.com/news/home/20260101831438/en/Takeda-and-Protagonist-Announce-Submission-of-New-Drug-Application-NDA-for-Rusfertide-for-Treatment-of-Polycythemia-Vera-PV",
      "catalyst_text": "Submitted FDA NDA for polycythemia vera treatment",
      "detailed_catalyst_text": "An NDA was submitted to the U.S. FDA seeking approval of rusfertide for adults with polycythemia vera. The filing follows positive Phase 3 VERIFY results and supports advancement into regulatory review for a potential new treatment option that may reduce phlebotomy burden and improve hematocrit control.",
      "catalyst_text_evidence": "Takeda and Protagonist Therapeutics announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults with polycythemia vera (PV). This NDA submission follows the positive 32-week primary analysis and 52-week results from the Phase 3 global randomized, placebo-controlled VERIFY study.",
      "news_published_at": "2026-01-06T00:00:00Z",
      "open_price_gap_percent": "0.00402",
      "intra_day_price_change_percent": "-0.03827"
    }
  ]
    }